Lipocine LPCN Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, Lipocine insiders bought $516,774 of stock on the open market (250.57K shares) and made no open-market sales.

• Counted by insider, open-market buying of LPCN stock in the past 12 months came from 2 insiders, with no insider selling.
• Among LPCN insiders, John W. Higuchi (Director) bought the most stock on the open market in the past 12 months: $415,524 (200.57K shares), most recently on September 30, 2026.
• Per Business Quant data, Lipocine insiders hold 405.88K shares in total based on their latest Form 4 filings, up 10.20% from 368.31K shares at the end of Q2 2026 and up 157.98% from 157.33K shares at the end of Q3 2025.
• Lipocine insiders report no indirect holdings: all 405.88K shares are held directly.
• Per Business Quant, 5 insiders of LPCN hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Lipocine's three biggest insider holders are John W. Higuchi (Director, 241.37K shares), Mahesh V. Patel (Chief Executive Officer, 160.68K shares) and Krista Fogarty (Principal Accounting Officer, 1.73K shares), based on their latest Form 4 filings.
• The holding of John W. Higuchi makes up 59.47% of all shares held by Lipocine insiders.
• Institutional investors held 36.15% of Lipocine stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 4.92%; other investors, including the public, hold roughly 58.93%.
• Over the past 12 months, 6 insiders reported transactions in Lipocine stock in 14 Form 4 filings.
• The insider data for LPCN reflects Form 4 filings through October 1, 2026.